Antigens, CD34

• 

  Subject Areas on Research

  • A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells. 
  • A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. 
  • A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. 
  • A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. 
  • A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. 
  • A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. 
  • Absence of phosphatidylinositol (PI)-linked proteins in a very early human multipotential haematopoietic marrow cell. 
  • Aging is not associated with bone marrow-resident progenitor cell depletion. 
  • Alteration of the CD34+ Tf-1 beta cell line profile in response to long-term exposure to IL-15. 
  • Alterations in colonic mucosal vessels in patients with cirrhosis and noncirrhotic portal hypertension. 
  • Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene. 
  • An effective strategy for decontamination, ex vivo expansion, and storage of human fetal liver hematopoietic stem cells. 
  • Apheresis. New opportunities. 
  • Auto-SCT for AML in second remission: CALGB study 9620. 
  • Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study. 
  • Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. 
  • CD34 and dural fibroblasts: the relationship to solitary fibrous tumor and meningioma. 
  • CD34 expression in desmoplastic melanoma. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • CD34+CD38-lin- cord blood cells develop into dendritic cells in human thymic stromal monolayers and thymic nodules. 
  • Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. 
  • Characterization of multiple CD34+ cell populations in cord blood. 
  • Circulating CD34+ cell counts are predictive of CD34+ peripheral blood progenitor cell yields. 
  • Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. 
  • Common endothelial progenitor cell assays identify discrete endothelial progenitor cell populations. 
  • Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells. 
  • Constitutive Stat3 activation alters behavior of hair follicle stem and progenitor cell populations. 
  • Cutaneous wound healing is impaired in hemophilia B. 
  • Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • Depletion of circulating progenitor cells precedes overt diabetes: a substudy from the VA enhanced fitness trial. 
  • Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry. 
  • Development and validation of a rapid, aldehyde dehydrogenase bright-based cord blood potency assay. 
  • Diagnosis of posttransplant granulocytic sarcoma by fine-needle aspiration cytology and flow cytometry. 
  • Differential effects of nitric oxide on erythroid and myeloid colony growth from CD34+ human bone marrow cells. 
  • Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts. 
  • Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. 
  • Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy. 
  • Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors. 
  • Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. 
  • Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. 
  • Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. 
  • Ex vivo expansion of murine and human hematopoietic stem cells. 
  • Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. 
  • Expression of protooncogene c-myb in normal human hematopoietic cells. 
  • Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. 
  • Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. 
  • Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. 
  • Gene therapy for immunodeficiency due to adenosine deaminase deficiency. 
  • Getting Back to Normal: Can Enhanced Regeneration Maintain Health? 
  • Gαq and hyper-phosphorylated ERK expression in Sturge-Weber syndrome leptomeningeal blood vessel endothelial cells. 
  • Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. 
  • High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). 
  • High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. 
  • High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. 
  • High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. 
  • Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. 
  • Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. 
  • Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75. 
  • Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. 
  • Increased numbers of total nucleated and CD34+ cells in blood group O cord blood: an analysis of neonatal innate factors in the Korean population. 
  • Increased transmigration of G-CSF-mobilized peripheral blood CD34+ cells after overnight storage at 37 degrees C. 
  • Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. 
  • Intradialytic hypertension and its association with endothelial cell dysfunction. 
  • Intramyocardial, autologous CD34+ cell therapy for refractory angina. 
  • Intraretinal neovascularization in diabetic retinopathy. 
  • Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. 
  • Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. 
  • Lack of circulating megakaryoblasts in newborn peripheral blood: development and validation of a sensitive flow cytometric detection method. 
  • Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation. 
  • Large-scale mobilization and isolation of CD34+ cells from normal donors. 
  • Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. 
  • Magnetic resonance imaging captures the biology of ductal carcinoma in situ. 
  • Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. 
  • Microvascular inflammation in renal allograft biopsies assessed by endothelial and leukocyte co-immunostain: a retrospective study on reproducibility and clinical/prognostic correlates. 
  • Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. 
  • Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. 
  • Molecular profile and partial functional analysis of novel endothelial cell-derived growth factors that regulate hematopoiesis. 
  • Multi-site evaluation of the BD Stem Cell Enumeration Kit for CD34(+) cell enumeration on the BD FACSCanto II and BD FACSCalibur flow cytometers. 
  • Multiparameter-fluorescence activated cell sorting analysis of retroviral vector gene transfer into primitive umbilical cord blood cells. 
  • New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. 
  • Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. 
  • Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. 
  • Peripheral blood stem cell harvesting and CD34-positive cell selection. 
  • Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. 
  • Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after nonmyeloablative transplantation with transduced autologous peripheral blood progenitor cells. 
  • Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. 
  • Positive selection of CD34+ hematopoietic progenitor cells for transplantation. 
  • Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. 
  • Progenitor cell dose determines the pace and completeness of engraftment in a xenograft model for cord blood transplantation. 
  • Progesterone receptor activity in leiomyomatosis peritonealis disseminata. 
  • Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Prospective isolation of bronchiolar stem cells based upon immunophenotypic and autofluorescence characteristics. 
  • Purification and partial characterization of a human hematopoietic precursor population. 
  • Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. 
  • Racial diversity with high nucleated cell counts and CD34 counts achieved in a national network of cord blood banks. 
  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. 
  • Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome. 
  • Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). 
  • Retroviral vector-mediated gene transfer into umbilical cord blood-derived megakaryocyte and platelet progenitors. 
  • Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. 
  • Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. 
  • Stem cell isolation. 
  • Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. 
  • Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues. 
  • Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. 
  • T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. 
  • The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. 
  • The effect of PIXY-321 on 4-hydroperoxycyclophosphamide purged and CD34+ positively selected bone marrow. 
  • The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties. 
  • Transplantation of CD34+ hematopoietic progenitor cells. 
  • Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. 
  • Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. 
  • Unmanipulated or CD34 selected haplotype mismatched transplants. 
  • Visible light optical spectroscopy is sensitive to neovascularization in the dysplastic cervix. 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor of Pediatrics, in the School of Medicine, Immunology